AstraZeneca take overs TeneoTwo to expand haematological cancer pipeline
Category: #health  | By Mateen Dalal  | Date: 2022-07-06 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca take overs TeneoTwo to expand haematological cancer pipeline

AstraZeneca has reportedly entered an agreement to acquire TeneoTwo, Inc., comprising TNB-486, Phase one clinical-stage T-cell engager, CD19/CD3, which is currently under assessment in refractory and relapsed B-cell non-Hodgkin lymphoma1.

As per reports, AstraZeneca is set to take over all exceptional equity of TeneoTwo by trading an open payment of $100 million on closing the deal.

As per the agreement terms, AstraZeneca will reportedly make an extra unforeseeable Research and Development-related benchmark payment of nearly $805 million along with another commercial-centric payment of around $360 million to the equity holders of TeneoTwo.

Notably, the procurement of TNB-486 aims to speed up the growth of this potential new medication for B-cell haematological malignancies, consisting follicular lymphoma and large B-cell lymphoma.

Mounting on the triumph of Calquence (acalabrutinib), TNB-486 further expands the haematology pipeline of AstraZeneca that spans various therapeutic mechanisms and modalities to meet a broad spectrum of blood cancers.

Not to mention, TNB-486 belongs to the group of therapeutic antibodies called T-cell engagers which are gaining prominence as promising therapeutic approaches amongst solid tumours and haematologic malignancies.

According to sources, T-cell engagers are considered bispecific molecules that are orchestrated to redirect the T-cells of the immune system to spot and eliminate cancer cells.

Moreover, by binding to the CD3 receptor on T-cells and CD19, which is an antigen that is expressed on B-cell, TNB-486 recruits and activates T-cells to CD19, forcing out tumours where they can stimulate an immune response.

Senior Vice President of Haematology Research and Development, AstraZeneca, Anas Younes, stated that TNB-486 either in combination with CD2O-targeted therapy or alone can possibly improvise patient results and intensify clinical responses by redirecting the body’s natural immune outcomes to target B-cell growths.

Overall, the acquisition will be reported as an intangible asset procurement, initially recognised at the current value of the non-contingent consideration with the anticipated benchmark capitalised in the intangible resources as they are recognised.

Source Credits: - http://www.cambridgenetwork.co.uk/news/astrazeneca-acquire-teneotwo-and-its-clinical-stage-t-cell-engager-strengthening-its

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

AWS and ATOS expand collaboration to achieve digital transformation faster

AWS and ATOS expand collaboration to achieve digital transformation faster

By Mateen Dalal

Amazon's subsidiary, Amazon Web Services, Inc. (AWS), has recently entered into a global Strategic Transformation Agreement with Atos, a leader in digital transformation, high-performance computing, and information technology infrastructure. This...

LadBible to lay off 10% of its workforce amid tough business conditions

LadBible to lay off 10% of its workforce amid tough business conditions

By Mateen Dalal

LadBible, one of the U.K.'s largest success stories in online media, is laying off 10% of its workforce as a result of a decline in its share price and a warning about difficult trading conditions. The Manchester-based corporation reportedly b...

Oral-B & iADH partner to make oral care positive & accessible for all

Oral-B & iADH partner to make oral care positive & accessible for all

By Mateen Dalal

Oral-B, a well-known American oral hygiene products brand, has reportedly inked a partnership deal with iADH (International Association of Disability and Oral Health), in order to make oral care more positive, accessible, and inclusive for disabled p...